Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab
Per Soelberg Sørensen(University of Copenhagen), Tomas Olsson(Karolinska University Hospital), Xavier Montalbán(Universitat de Vic - Universitat Central de Catalunya), Ludwig Kappos(University Hospital of Basel), Ralf Gold(St. Josef-Hospital), Eva Havrdová(Charles University), Gilles Edan(Centre National de la Recherche Scientifique), Antonio Bertolotto(Neuroscience Institute), Bernd C. Kieseier(Novartis (Switzerland)), Gavin Giovannoni(Queen Mary University of London)
Cited by 236
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis
|Annals of Neurology|2001|7k
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
|Annals of Neurology|2005|5k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k